Bristol-Myers Squibb Company stock gains traction as analysts raise targets on strong mezigdomide trial data

Analysts at Jefferies and HSBC have lifted price targets for Bristol-Myers Squibb Company (ISIN: US0897961004), spotlighting positive Phase 3 data from the SUCCESSOR-2 trial in multiple myeloma. The moves signal growing confidence in the company's oncology pipeline amid patent cliffs.

Bristol-Myers Squibb Company stock drew fresh analyst upgrades this week, driven by positive interim Phase 3 results from the SUCCESSOR-2 trial of oral mezigdomide in relapsed or refractory multiple myeloma. Jefferies raised its price target to $70 from $68 on the NYSE while maintaining a Buy rating, citing statistically significant progression-free survival improvements. HSBC followed with a target hike to $60 from $53, keeping a Hold. These updates come as the stock trades around $59.71 on the NYSE, highlighting investor interest in the biotech's next-generation therapies at a time when DACH investors seek stable dividend payers with growth potential in Europe's aging population.

As of: 18.03.2026

By Dr. Elena Voss, Senior Pharma Equity Analyst – 'Bristol-Myers Squibb's pipeline momentum in oncology positions it as a resilient pick for European portfolios navigating US market volatility.'

Breakthrough Data from SUCCESSOR-2 Trial

The SUCCESSOR-2 study tested mezigdomide, a novel CELMoD agent, combined with carfilzomib and dexamethasone against standard care in post-Revlimid patients. Results showed clinically meaningful progression-free survival gains, with Jefferies estimating a median delta exceeding four months. This marks a key step toward replacing traditional IMiDs like Revlimid, whose patents are expiring and eroding sales.

Bristol-Myers Squibb views mezigdomide as a potential backbone therapy in multiple myeloma. The company remains optimistic about the ongoing SUCCESSOR-1 trial versus Pomalyst, with data slated for 2027. Peak sales forecasts for mezigdomide now reach $758 million in this indication, assuming 70% success probability.

Multiple myeloma affects over 35,000 new patients annually in the US and Europe combined. Effective treatments are critical as the disease relapses frequently, driving demand for innovative agents like CELMoDs that offer superior degradation of disease-causing proteins.

Analyst Sentiment Shifts Upward

Jefferies' upgrade underscores the trial's interim readout as a de-risking event for Bristol-Myers Squibb's oncology franchise. The firm adjusted risk-adjusted forecasts upward, reflecting higher confidence in regulatory paths. Consensus now leans toward Outperform, with 29 analysts averaging a $62.64 target, implying over 4% upside from recent NYSE levels near $59.71.

HSBC's adjustment, while more conservative, acknowledges valuation improvements. Recent upward revisions in 2026 earnings estimates – 11 in the last 60 days – pushed consensus to $6.26 per share. Bristol-Myers Squibb's own FY2026 guidance stands at $6.05-6.35 EPS, with beats averaging 18.8% historically.

This cluster of updates within 48 hours amplifies market focus. Pharma stocks often rally on pipeline validation, especially when legacy revenues face pressure. Investors weigh these catalysts against broader sector dynamics like biosimilar competition.

Strategic Pipeline Beyond Multiple Myeloma

Bristol-Myers Squibb's immuno-oncology leadership persists with Opdivo driving label expansions in new cancers. Recent FDA approval of Sotyktu for psoriatic arthritis adds a immunology win, based on Phase 3 data showing superior response rates. Upcoming Milvexian Phase 3 results could disrupt anticoagulation markets dominated by Eliquis.

In multiple myeloma, the shift from IMiDs to CELMoDs addresses a market projected to exceed $30 billion globally by 2030. Bristol-Myers Squibb derives nearly 70% of sales from the US but eyes Europe for reimbursement tailwinds. Navlimetostat data in other indications further bolsters the pipeline diversity.

Revlimid erosion continues, but new launches offset declines. The company's VGM Score of B and Value Style Score of A attract bargain hunters, with forward P/E at 9.54 signaling undervaluation relative to peers.

Relevance for DACH Investors

German-speaking investors in Germany, Austria, and Switzerland prioritize pharma stocks for defensive qualities and dividends. Bristol-Myers Squibb's quarterly payout of $0.63 per share, payable May 1, 2026, yields competitively amid ECB rate uncertainty. Europe's multiple myeloma incidence rises with demographics, aligning with mezigdomide's profile.

DACH portfolios often hold US large-caps for diversification. Bristol-Myers Squibb fits as a holding company with global operations, trading primarily on NYSE in USD. Local brokers like Deutsche Bank or Swissquote facilitate access, with tax treaties easing withholding on dividends.

Recent institutional buying, such as Achmea Investment Management's stake increase, mirrors European fund flows into undervalued biotechs. For yield-focused DACH investors, the stock offers growth overlay on steady income, especially versus volatile tech names.

Key Risks and Open Questions

Patent cliffs loom large, with Revlimid, Pomalyst, and others facing generic entry. Bristol-Myers Squibb must execute launches flawlessly to sustain growth. SUCCESSOR-1 outcomes in 2027 carry binary risk if superiority over Pomalyst falters.

Regulatory hurdles persist in Europe, where EMA scrutiny on novel modalities like CELMoDs could delay approvals. Pricing pressures under IRA in the US and HTA in Germany challenge margins. Competition intensifies from Regeneron, Johnson & Johnson in myeloma.

Macro factors like US election outcomes or trade tensions impact 70% US-centric revenues. Investors monitor inventory cycles and R&D spend efficiency amid biotech funding squeezes.

Valuation and Long-Term Outlook

At recent NYSE prices around $59.71, the stock trades near 52-week highs of $62.89, up 32.7% over six months. Zacks Rank #3 Hold reflects balanced risk-reward. GF Value estimates suggest slight overvaluation at $53.85, but pipeline upside tempers concerns.

Consensus targets imply modest gains, but beats on EPS guidance could drive re-rating. For DACH investors, the blend of 4-5% yield, oncology catalysts, and value metrics supports accumulation on dips. Bristol-Myers Squibb's scale – as a leading biopharma – underpins resilience in downturns.

Broader sector tailwinds include AI-driven drug discovery accelerating pipelines. European reimbursement reforms may favor innovative myeloma therapies, enhancing accessibility.

Market Context and Positioning

Bristol-Myers Squibb differentiates through immuno-oncology dominance and cardiovascular staples like Eliquis, proven safer than rivals in recent studies. The firm's R&D focus on severe diseases aligns with global needs, from cancer to immunology.

Institutional interest grows, with funds boosting stakes amid positive revisions. For conservative DACH strategies, the stock serves as a core holding, balancing growth and income in diversified portfolios.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.